Combination therapy delays progression for metastatic breast cancer patients
 

Phase III trial results show that a combination of the aromatase inhibitor anastrozole and fulvestrant, an analog of estradiol that downgrades the estrogen receptor, is superior to anastrozole alone in prolonging progression-free survival in patients with metastatic breast cancer.

More...